Poor memory, negative symptoms and abnormal movements in never-treated Indian patients with schizophrenia

McCreadie, Robin G.; Latha, S; Rangaswamy, Thara; Padmavathi, R.; Ayankaran, J R

doi:10.1192/bjp.171.4.360

Cited by 38 publications

(14 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several studies have appeared over the past few years which have clearly indicated marked and severe cognitive impairment in patients who have been taken off their medication, or in patients who have never been prescribed any neuroleptic or anticholinergic medication (e.g. Blanchard & Neale, 1994;McCreadie et al, 1997;Saykin et al, 1994). Although drugs may make a contribution, they do not account for the cognitive impairment that is observed in schizophrenia.…”

Section: Is the Cognitive Impairment In Schizophrenia Caused By Medicmentioning

confidence: 99%

Cognitive impairment in schizophrenia

O’Carroll¹

2000

Adv. psychiatr. treat

102

View full text Add to dashboard Cite

show abstract

Section: Is the Cognitive Impairment In Schizophrenia Caused By Medicmentioning

confidence: 99%

Cognitive impairment in schizophrenia

O’Carroll¹

2000

Adv. psychiatr. treat

102

View full text Add to dashboard Cite

show abstract

“…There are few other studies of cognitive function in subjects with EPS prior to treatment. Older, never medicated subjects with dyskinesia appeared to have similar memory dysfunction on the Wechsler Memory Scale as those with no dyskinesia [23]. Global cognitive impairment was reported in three elderly, never medicated subjects [41].…”

Section: Discussionmentioning

confidence: 98%

“…Follow up studies over 18 months showed the movement disorders fluctuated over time, with 57% affected by dyskinesia and 35% affected by Parkinsonism on at least one assessment [22]. Dyskinesia was not related to memory dysfunction [23]. These patients showed enlargement of the left lentiform nucleus, and loss of the negative correlation between age and volumes of the caudate and lentiform nuclei [21].…”

mentioning

confidence: 99%

First episode psychosis with extrapyramidal signs prior to antipsychotic drug treatment

et al. 2011

View full text Add to dashboard Cite

Extrapyramidal movement disorders are common in chronic schizophrenia, and may be an intrinsic feature of the illness as well as related to antipsychotic drug treatment. Similar dysfunctions at illness onset may have implications for outcome, and for understanding the mechanisms of illness. The objectives were to examine the clinical correlates of pre-treatment movement disorders at first episode of psychosis, and determine associations with neuropsychological function and striatal structure. Never medicated subjects were recruited from consecutive admissions to Early Psychosis Programs with defined catchment areas in Hong Kong, China, and Halifax, Canada. Standardized clinical, neuropsychological and brain imaging assessments were carried out at baseline and following acute and long term treatment with typical or atypical antipsychotic drugs. At the Hong Kong site, we studied 84 subjects with first episode psychosis (n = 10 with EPS). At the Halifax site, we studied 40 subjects with first episode psychosis (n = 17 with EPS), and 23 healthy comparison subjects. Subjects with movement disorders prior to treatment (EPS+) had higher total PANSS scores at baseline (mean elevation 19.9% Hong Kong, P = 0.016; 14.7% Halifax, P = 0.049). In subjects treated with atypical antipsychotics (all Halifax), EPS+ status at baseline predicted more movement disorders at long term follow up (P = 0.0005). In both cohorts, EPS+ subjects had poorer acute symptomatic treatment response assessed with the PANSS (Hong Kong P = 0.005; Halifax P = 0.017). Neuropsychological impairment related to executive dysfunction appeared greater in a small sample of EPS+ subjects (Hong Kong, effect size 0.26-0.27, P < 0.05). Caudate volumes were 4.5% larger in EPS+ compared with EPS-subjects (Halifax P = 0.042), and correlations between striatal volumes and age were different in the EPS+ group. In conclusion, pre-treatment EPS is present in a substantial minority of subjects with first episode psychosis, appears to persist at long term follow up, and is associated with poorer response of symptoms to treatment. Selective impairment of executive function and striatal enlargement provides evidence of abnormalities of brain function and structure associated with this aspect of early psychosis. schizophrenia, movement disorder, basal ganglia, antipsychotics, cognitive, psychosis Citation:Honer W G, Lang D J, Kopala L C, et al. First episode psychosis with extrapyramidal signs prior to antipsychotic drug treatment.

show abstract

“…Several studies have appeared over the years which have indicated marked and severe cognitive impairment in patients who have been taken off their medication, or in patients who have never been prescribed any neuroleptic or anticholinergic medication 18,19 . Thus, although drugs may make a contribution, they do not account for the cognitive impairment that is observed in schizophrenia.…”

Section: Is the Cognitive Impairment In Schizophrenia Caused By Medicmentioning

confidence: 99%

“…Few Indian studies are available in relation to cognitive deficits in schizophrenia 18,57,58 . Most of them are replication studies of that has already been reported in western literature.…”

Section: Indian Studies On Cognitive Deficit In Schizophreniamentioning

confidence: 99%